AngioDynamics hopes to add $50m to top-line in five years with Vortex buy
This article was originally published in Clinica
Executive Summary
Vascular disease specialist AngioDynamics has gained a technology to remove blood clots that could bring in revenues of $50 million within five years, with its $15 million acquisition of Vortex Medical.